Search Options Stock News and Analysis from Schaeffer's

ABBV Options Traders React to Piper Jaffray Upgrade

https://www.schaeffersresearch.com/content/options/2019/08/20/abbv-options-traders-react-to-piper-jaffray-upgrade

8/20/2019 1:48 PM

Abbvie Inc (NYSE:ABBV) is trying to recover from last week's two-year low, getting a boost today from an upgrade to "overweight" from "neutral" at Piper Jaffray, which also set an $80 price target. Th...

Merck Stock Earns Another Bull Note

https://www.schaeffersresearch.com/content/news/2019/07/03/merck-stock-earns-another-bull-note

7/3/2019 10:35 AM

The shares of Merck & Co, Inc. (NYSE:MRK) have had a huge year, riding the tailwinds from the company's blockbuster cancer drug Keytruda. The drug is one reason another analyst is saying the stock is...

Allergan Options Bull Wins Big on AbbVie Buyout Buzz

https://www.schaeffersresearch.com/content/options/2019/06/25/allergan-options-bull-wins-big-on-abbvie-buyout-buzz

6/25/2019 2:53 PM

Wall Street is buzzing today with news of Abbvie Inc's (NYSE:ABBV) $63 billion buyout bid for Allergan plc (NYSE:AGN). The news has AGN stock at the top of the Big Board, and options traders swarmin...

Dow Trades Lower Ahead of Powell

https://www.schaeffersresearch.com/content/ezines/2019/06/25/dow-trades-lower-ahead-of-powell

6/25/2019 12:01 PM

The Dow Jones Industrial Average (DJI) is modestly lower midday after a dismal batch of economic reports hit ahead of this afternoon's speech from Fed Chair Jerome Powell. Specifically, an S&P Core...

Analysts Pile On Allergan Stock After Weak Drug Data

https://www.schaeffersresearch.com/content/news/2019/03/07/analysts-pile-on-allergan-stock-after-weak-drug-data

3/7/2019 10:15 AM

Allergan plc (NYSE:AGN) is up 4.2% to trade at $143.31, shaking off some subpar drug data. Specifically, Rapastinel, the company's depression treatment, failed three late-stage studies. However, AGN s...

PEOPLE ALSO SEARCH FOR